F
39
-8
AXP
60
-4
EL
25
-14
IP
71
14
NTRS
50
-5
NSC
50
-4
VNO
61
-4
MDT
59
-3
FRT
34
-9
ETN
67
-6
GE
58
-2
CNX
69
-4
AMAT
41
-3
SYY
41
2
MAR
57
-6
USB
48
-5
PHM
55
-2
DG
21
2
PNW
66
2
GRMN
70
-4
F
39
-8
AXP
60
-4
EL
25
-14
IP
71
14
NTRS
50
-5
NSC
50
-4
VNO
61
-4
MDT
59
-3
FRT
34
-9
ETN
67
-6
GE
58
-2
CNX
69
-4
AMAT
41
-3
SYY
41
2
MAR
57
-6
USB
48
-5
PHM
55
-2
DG
21
2
PNW
66
2
GRMN
70
-4
Financhill
Back

Outlook Therapeutics 10K Form

Sell
25

OTLK
Outlook Therapeutics

Last Price:
5.76
Seasonality Move:
-12.63%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive OTLK News And Ratings

See the #1 stock for the next 7 days that we like better than OTLK

OTLK Financial Statistics

Sales & Book Value

Annual Sales: $8.15M
Cash Flow: $-19.51M
Price / Cash Flow: 0
Annual Sales: $-3.57
Price / Book: 0

Profitability

EPS (TTM): -10.77000
Net Income (TTM): $-94.05M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Outlook Therapeutics Earnings Forecast

Key Outlook Therapeutics Financial Ratios

  • The Interest Expense is -2.64% of Operating Income.
  • Per Share Earnings over the last 10 years have been positive in 7 years.

Outlook Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: OTLK
CUSIP: 69012T
Website: outlooktherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

OTLK Technical Analysis vs Fundamental Analysis

Sell
25
Outlook Therapeutics (OTLK) is a Sell

Is Outlook Therapeutics a Buy or a Sell?